Company intelligence / Profile preview
Bayhill Therapeutics, Inc.
Palo Alto, California, United Statespappas-capital.com ↗
- Ownership
- Private
- Employees
- ~75
- Development stage
- Phase 2
01
Overview
Interim results of a Phase I/II trial for BHT-3021 in type 1 diabetes showed preservation of C-peptide in treated patients compared to placebo, and the treatment was safe and well-tolerated among 42 patients who received different doses over 12 weeks[6]
- Therapeutic areas
- NeurologyImmunologyEndocrinology
- Modalities
- DNA-based vaccinesoligonucleotidesantigen-specific immunotherapies
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Genentech ($350 million agreement for BHT-3021)[6]
Beyond the preview
Go deeper on Bayhill Therapeutics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bayhill Therapeutics, Inc..